title: Physicochemical action of potassium-magnesium citrate in nephrolithiasis.
abstract: Effect of potassium-magnesium citrate on urinary biochemistry and crystallization of stone-forming salts was compared with that of potassium citrate at same dose of potassium in five normal subjects and five patients with calcium nephrolithiasis. Compared to the placebo phase, urinary pH rose significantly from 6.06 +/- 0.27 to 6.48 +/- 0.36 (mean +/- SD, p less than 0.0167) during treatment with potassium citrate (50 mEq/day for 7 days) and to 6.68 +/- 0.31 during therapy with potassium-magnesium citrate (containing 49 mEq K, 24.5 mEq Mg, and 73.5 mEq citrate per day). Urinary pH was significantly higher during potassium-magnesium citrate than during potassium citrate therapy. Thus, the amount of undissociated uric acid declined from 118 +/- 61 mg/day during the placebo phase to 68 +/- 54 mg/day during potassium citrate treatment and, more prominently, to 41 +/- 46 mg/day during potassium-magnesium citrate therapy. Urinary magnesium rose significantly from 102 +/- 25 to 146 +/- 37 mg/day during potassium-magnesium citrate therapy but not during potassium citrate therapy. Urinary citrate rose more prominently during potassium-magnesium citrate therapy (to 1027 +/- 478 mg/day from 638 +/- 252 mg/day) than during potassium citrate treatment (to 932 +/- 297 mg/day). Consequently, urinary saturation (activity product) of calcium oxalate declined significantly (from 1.49 x 10(-8) to 1.03 x 10(-8) M2) during potassium-magnesium citrate therapy and marginally (to 1.14 x 10(-8) M2) during potassium citrate therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas.
authors.forename: C Y
authors.initials: CY
authors.lastname: Pak
authors.forename: K
authors.initials: K
authors.lastname: Koenig
authors.forename: R
authors.initials: R
authors.lastname: Khan
authors.forename: S
authors.initials: S
authors.lastname: Haynes
authors.forename: P
authors.initials: P
authors.lastname: Padalino
mesh_terms: D000328:Adult; D000368:Aged; D002951:Citrates / Q000494:pharmacology*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007669:Kidney Calculi / Q000188:drug therapy* / Q000652:urine; D008274:Magnesium / Q000494:pharmacology*; D017616:Magnesium Compounds; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000494:pharmacology*; D017680:Potassium Compounds
chemical_list: D002951:Citrates; D004338:Drug Combinations; D017616:Magnesium Compounds; D017680:Potassium Compounds; D008274:Magnesium; D011188:Potassium; C066902:potassium-magnesium citrate